These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20927616)

  • 21. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
    Pledgie-Tracy A; Billam M; Hacker A; Sobolewski MD; Woster PM; Zhang Z; Casero RA; Davidson NE
    Cancer Chemother Pharmacol; 2010 May; 65(6):1067-81. PubMed ID: 19727732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioactivity-guided identification and cell signaling technology to delineate the lactate dehydrogenase A inhibition effects of Spatholobus suberectus on breast cancer.
    Wang Z; Wang D; Han S; Wang N; Mo F; Loo TY; Shen J; Huang H; Chen J
    PLoS One; 2013; 8(2):e56631. PubMed ID: 23457597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
    Scaltriti M; Serra V; Normant E; Guzman M; Rodriguez O; Lim AR; Slocum KL; West KA; Rodriguez V; Prudkin L; Jimenez J; Aura C; Baselga J
    Mol Cancer Ther; 2011 May; 10(5):817-24. PubMed ID: 21383049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A compound that inhibits the HOP-Hsp90 complex formation and has unique killing effects in breast cancer cell lines.
    Pimienta G; Herbert KM; Regan L
    Mol Pharm; 2011 Dec; 8(6):2252-61. PubMed ID: 21882818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
    Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J
    BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virtual screening based identification of miltefosine and octenidine as inhibitors of heat shock protein 90.
    Li L; Yang M; Li C; Liu Y
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Nov; 394(11):2223-2232. PubMed ID: 34406420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
    Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
    Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells.
    Berthe A; Zaffino M; Muller C; Foulquier F; Houdou M; Schulz C; Bost F; De Fay E; Mazerbourg S; Flament S
    Breast Cancer Res Treat; 2018 Oct; 171(3):581-591. PubMed ID: 29971627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.
    Liu YM; Tu HJ; Wu CH; Lai MJ; Yu SC; Chao MW; Wu YW; Teng CM; Pan SL; Liou JP
    Eur J Med Chem; 2021 Jul; 219():113428. PubMed ID: 33934008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
    Fiskus W; Ren Y; Mohapatra A; Bali P; Mandawat A; Rao R; Herger B; Yang Y; Atadja P; Wu J; Bhalla K
    Clin Cancer Res; 2007 Aug; 13(16):4882-90. PubMed ID: 17699868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo.
    Wang W; Liu Y; Zhao Z; Xie C; Xu Y; Hu Y; Quan H; Lou L
    Cancer Sci; 2016 Jun; 107(6):782-90. PubMed ID: 27002306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells.
    Sisinni L; Maddalena F; Lettini G; Condelli V; Matassa DS; Esposito F; Landriscina M
    Int J Oncol; 2014 Feb; 44(2):573-82. PubMed ID: 24297638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide.
    Horibe T; Torisawa A; Kohno M; Kawakami K
    BMC Cancer; 2014 Aug; 14():615. PubMed ID: 25159299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors.
    Bizarro A; Sousa D; Lima RT; Musso L; Cincinelli R; Zuco V; De Cesare M; Dallavalle S; Vasconcelos MH
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29438315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.
    Gougelet A; Bouclier C; Marsaud V; Maillard S; Mueller SO; Korach KS; Renoir JM
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):71-81. PubMed ID: 15862952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
    Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
    Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo.
    Menezes DL; Taverna P; Jensen MR; Abrams T; Stuart D; Yu GK; Duhl D; Machajewski T; Sellers WR; Pryer NK; Gao Z
    Mol Cancer Ther; 2012 Mar; 11(3):730-9. PubMed ID: 22246440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.